Indivior Pharmaceuticals and Supernus Pharmaceuticals have merged. Learn More Here

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

April 9, 2026

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Access to the Live Webcast Presentation:

The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.

Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp

Participants may access the presentation telephonically by registering with the following link:

https://register-conf.media-server.com/register/BIea9b995134de41e68f49a057c2a6cb66

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

A replay of the presentation will be available at www.indivior.com.

About Indivior 
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior. 

For Further Information

Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com


Primary Logo

Source: Indivior Pharmaceuticals Inc.

Indivior merger with Supernus Pharmaceuticals

Supernus Logo

As of November 2, 2026, Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have successfully completed their merger of equals transaction, creating a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, financial flexibility and capacity to pursue growth opportunities, and a differentiated pipeline. The combined company will operate as Supernus, Inc. and will trade on the Nasdaq Global Select Market beginning on November 3, 2026, under the ticker symbol "SUPN".

Learn more about the merger